Loss of the EP2 prostaglandin E2 receptor in immortalized human keratinocytes results in increased invasiveness and decreased paxillin expression.
Prostaglandin E(2) (PGE(2)) receptor subtype EP(2), which is coupled to cAMP metabolism, is known to mediate proliferation of primary human keratinocytes in vitro. The effect of gain or loss of EP(2) receptors in immortalized human keratinocytes (HaCat cells) was examined. HaCat keratinocytes were transfected with sense or anti-sense constructs of the EP(2) receptor. Loss or gain of EP(2) expression was documented by immunoblot and associated changes in agonist-stimulated cAMP production. Loss or gain of EP(2) receptor expression correlated with alterations in plating efficiencies but with modest affects on growth. When cell lines were studied in an organ culture model, anti-sense clones were highly invasive compared with vector controls and sense transfectants. A marked increase in prostaglandin production is commonly seen in malignant lesions. Because prostaglandin receptors are known to undergo ligand-induced receptor down-regulation, we sought to determine whether EP(2) receptor down-regulation results in increased invasiveness. In vector controls, invasiveness was reproduced by ligand-dependent EP(2) receptor down-regulation as assessed by immunohistochemistry. In addition, loss of EP(2) receptor expression was associated with decreased paxillin expression, a critical component of focal adhesion assembly. Thus, down-regulation of EP(2) receptors represents a potential mechanism for neoplastic progression to an invasive phenotype.
Konger
Raymond L
RL
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 406 Fesler Hall, 1120 South Drive, Indianapolis, IN 46202, USA. rkonger@iupui.edu
Scott
Glynis A
GA
Landt
Yvonne
Y
Ladenson
Jack H
JH
Pentland
Alice P
AP
D000527:Alprostadil / Q000031:analogs & derivatives / Q000378:metabolism; D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism; D002460:Cell Line; D048429:Cell Size; D002471:Cell Transformation, Neoplastic; D000242:Cyclic AMP / Q000378:metabolism; D003598:Cytoskeletal Proteins / Q000378:metabolism*; D016373:DNA, Antisense / Q000378:metabolism; D015536:Down-Regulation / Q000502:physiology; D005347:Fibroblasts / Q000166:cytology / Q000378:metabolism; D005822:Genetic Vectors; D006801:Humans; D015603:Keratinocytes / Q000166:cytology / Q000378:metabolism*; D051419:Paxillin; D010641:Phenotype; D010750:Phosphoproteins / Q000378:metabolism*; D018078:Receptors, Prostaglandin E / Q000235:genetics / Q000378:metabolism*; D058307:Receptors, Prostaglandin E, EP2 Subtype; D012867:Skin / Q000166:cytology / Q000378:metabolism
D000911:Antibodies, Monoclonal; D003598:Cytoskeletal Proteins; D016373:DNA, Antisense; C545644:PTGER2 protein, human; C496061:PXN protein, human; D051419:Paxillin; D010750:Phosphoproteins; D018078:Receptors, Prostaglandin E; D058307:Receptors, Prostaglandin E, EP2 Subtype; D000242:Cyclic AMP; D000527:Alprostadil